Article Details

Merck keeps deal focus with Keytruda patent cliff on horizon - BioPharma Dive

Retrieved on: 2024-02-01 17:22:11

Tags for this article:

Click the tags to see associated articles and topics

Merck keeps deal focus with Keytruda patent cliff on horizon - BioPharma Dive. View article details on hiswai:

Excerpt

The company is open to acquisitions of up to $15 billion, company CEO Rob Davis said Thursday on a fourth quarter earnings call. Published Feb.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up